
Quarterly report 2022-Q3
added 11-10-2022
Viveve Medical Revenue 2011-2026 | VIVE
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Viveve Medical
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 6.43 M | 5.48 M | 6.57 M | 18.5 M | 15.3 M | 7.14 M | 1.45 M | 90 K | 1.27 M | 1.08 M | 671 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.5 M | 90 K | 5.82 M |
Quarterly Revenue Viveve Medical
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 1.68 M | 1.8 M | 1.64 M | - | 1.62 M | 1.65 M | 1.45 M | - | 1.52 M | 704 K | 1.3 M | - | 1.05 M | 1.05 M | 3.01 M | - | 4.82 M | 5.52 M | 3.7 M | - | 4.07 M | 3.08 M | 3.04 M | - | 1.85 M | 1.56 M | 1.28 M | - | 584 K | 73 K | 38 K | - | 17 K | 73 K | 47 K | - | 4.61 K | 372 K | 348 K | - | 212 K | 363 K | 20 K | - | 27 K | 398 K | 57 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.52 M | 4.61 K | 1.39 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Abiomed
ABMD
|
848 M | - | - | $ 17.2 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Alphatec Holdings
ATEC
|
612 M | $ 21.04 | 0.86 % | $ 3.01 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Apyx Medical Corporation
APYX
|
52.3 M | $ 3.5 | 1.74 % | $ 121 M | ||
|
Cognyte Software Ltd.
CGNT
|
443 M | $ 9.4 | 1.08 % | $ 675 M | ||
|
Boston Scientific Corporation
BSX
|
16.7 B | $ 95.35 | -0.69 % | $ 140 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
2.57 B | $ 302.99 | -0.5 % | $ 8.55 B | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 47.11 | -0.84 % | $ 7.02 K | ||
|
Electromed
ELMD
|
64 M | $ 29.12 | 1.01 % | $ 246 M | ||
|
Abbott Laboratories
ABT
|
42 B | $ 125.29 | -0.39 % | $ 218 B | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.29 | 2.49 % | $ 123 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
IRadimed Corporation
IRMD
|
73.2 M | $ 97.28 | -0.5 % | $ 1.23 B | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Zynex
ZYXI
|
192 M | - | - | $ 21.1 M | ||
|
InMode Ltd.
INMD
|
358 M | $ 14.69 | -1.01 % | $ 1.17 B | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Align Technology
ALGN
|
4 B | $ 156.15 | -1.26 % | $ 11.7 B | ||
|
Accuray Incorporated
ARAY
|
459 M | $ 0.82 | 2.64 % | $ 84.3 M | ||
|
LivaNova PLC
LIVN
|
1.25 B | $ 61.53 | -1.2 % | $ 3.34 B | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
LENSAR
LNSR
|
53.5 M | $ 11.63 | - | $ 134 M | ||
|
ClearPoint Neuro
CLPT
|
31.4 M | $ 13.68 | 0.81 % | $ 370 M | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.56 | -0.22 % | $ 122 M | ||
|
AxoGen
AXGN
|
187 M | $ 32.73 | - | $ 1.45 B | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.14 | -0.87 % | $ 18.4 M | ||
|
CONMED Corporation
CNMD
|
1.31 B | $ 40.6 | -1.31 % | $ 1.25 B | ||
|
OrthoPediatrics Corp.
KIDS
|
205 M | $ 17.76 | -1.11 % | $ 410 M | ||
|
Globus Medical
GMED
|
2.52 B | $ 87.31 | -0.68 % | $ 11.9 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 12.42 | -2.05 % | $ 956 M | ||
|
Myomo
MYO
|
1 B | $ 0.91 | -1.58 % | $ 6.42 M |